Join the Imedex Network!

QUICK POLL

If imatinib, nilotinib, and dasatinib are all approved for front-line therapy of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), what would you recommend as front-line therapy for a 42-year-old man who presents with high-risk CML by both the Sokal and Hasford (Euro) scoring systems and who has no matched sibling donor?

Join the Imedex Network!

Membership in our network is complimentary. By becoming a member, you will have unlimited, free access to our website and e-learning activities by visiting elc.imedex.com. In addition, you will be added to the distribution list for all Imedex products and services that apply to your specialty. If you wish to be removed from one or more of our distribution lists, please contact Imedex Customer Service at meetings@imedex.com.

** Denotes required fields.

Account Details

Given Name**	Family Name**	Degree(s)

Email**	Confirm Email**

Password**	Confirm Password**
		REQ: Min. 6 characters, 1 capital letter, and 1 number.

Mailing Address

Street Address	City**	State**

	Country**	Postal Code**

Professional Information

Company/Practice Name**	Company/Practice Type**	Position

Profession**	Specialty**	Subspecialty (Oncology only)